^
Association details:
Evidence:
Evidence Level:
Sensitive: C2 – Inclusion Criteria
Title:

A Phase II Single Arm Pilot Study of the Chk1/2 Inhibitor (LY2606368) in BRCA1/2 Mutation Associated Breast or Ovarian Cancer, Triple Negative Breast Cancer, High Grade Serous Ovarian Cancer, and Metastatic Castrate-Resistant Prostate Cancer

Excerpt:
...Participants enrolling in the sporadic high grade serous epithelial or high grade endometrioid ovarian cancer group, Cohort 2, must have a negative family history of hereditary breast ovarian cancer (HBOC) syndrome, or negative gBRCA1/2m mutation test....
Trial ID:
Evidence Level:
Sensitive: D – Preclinical
Title:

BLM overexpression as a predictive biomarker for CHK1 inhibitor response in PARP inhibitor–resistant BRCA-mutant ovarian cancer

Published date:
06/21/2023
Excerpt:
The aim of this study was to investigate the clinical activity of CHK1i prexasertib in PARPi-resistant BRCA-mutant HGSC and to identify potential biomarkers for CHK1i response….IC50 values for prexasertib monotherapy ranged from 1.2 to 30.6 nM in PARPi-sensitive and -resistant BRCA-mutant HGSC cells...
DOI:
10.1126/scitranslmed.add7872